The increasing demand for CLIA-waived molecular POC tests, increasing public awareness levels pertaining to pre-disease detection and increasing focus on decentralized diagnostics are the primary growth drivers for point of care molecular diagnostics market. It has become feasible to detect numerous viral and bacterial organisms precisely from a patient specimen with the launch of amplification methods for other nucleic acid and polymerase chain reaction. The Clinical Laboratory Improvement Amendments (CLIA) is the regulation for all the U.S. facilities which test human specimens.